Home
ADTX
ADTX News

Latest Aditxt Inc. (ADTX) News on September 3, 2025

Business Wire

2 months ago

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Business Wire

3 months ago

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

Business Wire

3 months ago

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

GlobeNewswire

3 months ago

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Business Wire

3 months ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Business Wire

4 months ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Business Wire

5 months ago

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Business Wire

5 months ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Business Wire

5 months ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Business Wire

5 months ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Why Aditxt Inc. (ADTX) Went Down On Thursday?

Insider Monkey

5 months ago

Why Aditxt Inc. (ADTX) Went Down On Thursday?

Business Wire

5 months ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

GlobeNewswire

5 months ago

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

Business Wire

5 months ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Business Wire

5 months ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

PR Newswire

5 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Business Wire

5 months ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

GlobeNewswire

6 months ago

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Business Wire

6 months ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Business Wire

6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Business Wire

6 months ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt subsidiary Persanta engages Dominary Securities for IPO

TipRanks

6 months ago

Aditxt subsidiary Persanta engages Dominary Securities for IPO

Business Wire

6 months ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Business Wire

7 months ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Business Wire

8 months ago

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Business Wire

9 months ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

GlobeNewswire

9 months ago

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

PR Newswire

10 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

GlobeNewswire

10 months ago

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Business Wire

10 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Business Wire

10 months ago

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

GlobeNewswire

10 months ago

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Business Wire

10 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

PR Newswire

10 months ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Business Wire

10 months ago

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

GlobeNewswire

10 months ago

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Business Wire

10 months ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Business Wire

10 months ago

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

Business Wire

10 months ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Business Wire

10 months ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy

TipRanks

a year ago

Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy

Business Wire

a year ago

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Business Wire

a year ago

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Business Wire

a year ago

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Business Wire

a year ago

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Business Wire

a year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Business Wire

a year ago

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Business Wire

a year ago

Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Business Wire

a year ago

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Business Wire

a year ago

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Business Wire

a year ago

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Business Wire

a year ago

Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

Business Wire

a year ago

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

PR Newswire

a year ago

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Business Wire

a year ago

Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans

Business Wire

a year ago

Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Business Wire

a year ago

Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Business Wire

a year ago

Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

GlobeNewswire

a year ago

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

Business Wire

a year ago

Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

PR Newswire

a year ago

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

Business Wire

a year ago

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

PR Newswire

a year ago

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Unifor members vote to strike at Manitoba Hydro

CNW Group

a year ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly

AFP

a year ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Business Insider

a year ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

PR Newswire

a year ago

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

Business Wire

a year ago

CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire

a year ago

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

PR Newswire

a year ago

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

PR Newswire

a year ago

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

PR Newswire

2 years ago

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Business Wire

2 years ago

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

PR Newswire

2 years ago

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

Rave Restaurant Group Insider Ups Holding During Year

Simply Wall St.

2 years ago

Rave Restaurant Group Insider Ups Holding During Year

Monarch Truck Center to Host Ride and Drive of REE’s P7-C for Canteen, Stanford University, City of San Jose and Other Large Fleet Customers in the Bay Area

GlobeNewswire

2 years ago

Monarch Truck Center to Host Ride and Drive of REE’s P7-C for Canteen, Stanford University, City of San Jose and Other Large Fleet Customers in the Bay Area

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Business Wire

2 years ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

The 3 Most Undervalued AI Stocks to Buy in January

InvestorPlace

2 years ago

The 3 Most Undervalued AI Stocks to Buy in January

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

GlobeNewswire

2 years ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

GlobeNewswire

2 years ago

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

Hycroft Delivers More High-Grade - Expands New Silver System at Brimstone

PR Newswire

2 years ago

Hycroft Delivers More High-Grade - Expands New Silver System at Brimstone

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Business Wire

2 years ago

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Business Wire

2 years ago

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire

2 years ago

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

Business Wire

2 years ago

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

GlobeNewswire

2 years ago

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

Does HomeTrust Bancshares (NASDAQ:HTBI) Deserve A Spot On Your Watchlist?

Simply Wall St.

2 years ago

Does HomeTrust Bancshares (NASDAQ:HTBI) Deserve A Spot On Your Watchlist?

3 Moonshot Stocks to Invest in the Future of Space Exploration

InvestorPlace

2 years ago

3 Moonshot Stocks to Invest in the Future of Space Exploration

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

ACCESSWIRE

2 years ago

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

Veru Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 years ago

Veru Announces Proposed Public Offering of Common Stock

United-Guardian, Inc. (NASDAQ:UG) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Simply Wall St.

2 years ago

United-Guardian, Inc. (NASDAQ:UG) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Business Wire

2 years ago

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

GlobeNewswire

2 years ago

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

GlobeNewswire

2 years ago

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

GlobeNewswire

2 years ago

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

Share on Social Networks: